JOINT STATEMENT on the signing of a Memorandum of Understanding
Brussels, September 13th, 2018
The two Innovative Medicines Initiative (IMI) consortia PARADIGM, Patients Active in Research and Dialogues for an Improved Generation of Medicine (co-led by the European Patients’ Forum and the European Federation of Pharmaceutical Industries and Associations) and PREFER, Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (co-led by Uppsala University and Novartis) have established a Memorandum of Understanding aiming to enhance the cooperation and collaboration between the two projects.
While PARADIGM is broadly focused on patient engagement at three points in the R&D process, PREFER looks at how and when it is best to perform and include patient preferences in decision making during the medical product life cycle. The nexus certainly can be found in terms of content as well as process. The intent is to (i) identify areas of mutual interest; (ii) identify any gaps that are hindering progress; (iii) establish collaborative activities that can address gaps; (iv) share knowledge and relevant data; (v) mutually participate in project events, and; (vi) utilize each projects communication channels to disseminate news, outcomes, and the overall results of these collaborations.
There is an ample opportunity to leverage the work of these projects, to avoid duplicate efforts as well as maximize results. This is one of the first Memorandum of Understanding between two ongoing public-private partnerships. Being part of the Innovative Medicines Initiative, PARADIGM and PREFER are set to make patient engagement in medicines R&D a greater reality.
– – – –
The PARADIGM project’s mission is to provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engagement (PE) and demonstrates the ‘return on the engagement’ for all players. More information on the PARADIGM website, on Twitter and LinkedIn.
The PREFER will establish recommendations to support development of guidelines for industry, Regulatory Authorities and HTA bodies on how and when to include patient perspectives on benefits and risks of medicinal products. More information on the PREFER website and on Twitter.
- For PARADIGM: Mathieu Boudes, European Patients’ Forum, email@example.com, www.imi-paradigm.eu
- For PREFER: Mats G. Hansson. Uppsala University, firstname.lastname@example.org, www.imi-prefer.eu
- For IMI: email@example.com
This text and its contents reflects the PARADIGM and PREFER projects’ view and not the view of IMI, the European Union or EFPIA.
The Patients Active in Research and Dialogues for an Improved Generation of Medicines (PARADIGM project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777450. The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.